The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event

Trial Profile

The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Acronyms ReTreatment
  • Sponsors Novartis
  • Most Recent Events

    • 09 Feb 2016 Status changed from completed to discontinued ClinicalTrials.gov record.
    • 23 Mar 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
    • 05 Feb 2015 Planned End Date changed from 1 Apr 2016 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top